Anyone familiar with Ozempic or Wegovy knows the core problem: these drugs work, but they require injections. As of April 1, 2026, there is an alternative. The FDA has approved Foundayo, a daily pill from Eli Lilly that uses the same mechanism of action without a needle. In clinical trials, participants lost an average of 12.4 percent of their body weight, compared with 0.9 percent in the placebo group.
What makes Foundayo different
Previous drugs in this class are based on peptides, small proteins that the digestive system breaks down before they can reach the bloodstream. That is why they had to be injected. Foundayo's active ingredient, orforglipron, is chemically different: as a small molecule, it survives passage through the stomach and can be taken orally.
The difference sounds technical but has practical consequences. Foundayo can be taken at any time of day, regardless of meals or how much water you drink. Earlier pill attempts in this drug class, such as Novo Nordisk's Rybelsus, required strict dosing rules: on an empty stomach, at least 30 minutes before breakfast, with only a small sip of water. In practice, that reduced effectiveness for many patients considerably.
Eli Lilly made Foundayo available through its direct program LillyDirect from April 6, 2026. With commercial health insurance, a monthly supply starts at $25. Without insurance, the price is $149, far below the more than $1,300 that Wegovy costs monthly without rebates.
Approved in record time
The FDA granted approval 50 days after the application was filed. According to the agency, that is the fastest approval for a new molecular entity since 2002. The speed was made possible through the National Priority Voucher program, a pilot initiative from the FDA Commissioner for particularly significant new compounds.
The rapid approval is notable on its own. Less well known is what followed: on April 14, 2026, two weeks after the approval, the FDA requested additional safety data from Eli Lilly. That is not unusual after expedited reviews, but it signals that the agency is continuing to monitor long-term data closely. The company and the agency have agreed on a timeline for the data submission; the approval itself is not in question.
What the study data show
The pivotal trial for approval, Attain-1, ran for 72 weeks. Participants taking Foundayo lost an average of 27.3 pounds, roughly 12.4 kilograms. The placebo group lost 2.2 pounds. At the highest dose, weight loss reached up to 11.2 percent of starting body weight.
For comparison: Wegovy, Novo Nordisk's injectable semaglutide, achieves weight losses of 15 to 17 percent in trials. Foundayo is therefore somewhat less effective, but offers considerable advantages in ease of use and cost. For the millions of people who cannot tolerate injections or cannot afford monthly medication costs exceeding a thousand dollars, that difference is real.
The most common side effects in the trial were nausea, diarrhea and vomiting, the same gastrointestinal complaints known from other drugs in this class. In most cases they were temporary, occurring mainly in the first weeks of treatment.
A market in motion
This market is now one of the fastest-growing segments of the pharmaceutical industry. Novo Nordisk and Eli Lilly have shared it almost entirely until now. With Foundayo, the competitive picture shifts: while Novo Nordisk's injectable products remain more effective, Eli Lilly is offering for the first time a low-barrier entry option accessible to a much broader population.
The approval covers adults with a body mass index of 30 or higher, or a BMI of 27 or above with at least one weight-related condition such as high blood pressure or type 2 diabetes. Whether Foundayo will receive additional indications, including cardiovascular risk reduction as Wegovy has, depends on ongoing studies whose results are expected in 2027.